Revenues in the first half are significantly ahead of the equivalent period in 2015 driven principally by strong sales of our TMT® reagents. We received our largest ever TMT® order and associated royalty payment in Q2, but the introduction of higher plexing solutions (new reagents which enable the parallel analysis of more biological samples) is now unlikely to occur before the end of 2017 because of the high demand for our current TMT® reagent synthesis. This is not expected to have a material impact on 2016 revenues and biomarker services contracts, particularly those using TMTcalibrator™, remain solid. Read More.

Proteome Sciences plc published this content on 28 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 28 July 2016 07:16:16 UTC.

Original documenthttp://www.proteomics.com/news-and-events/news/post/trading-update-and-notice-of-results

Public permalinkhttp://www.publicnow.com/view/5A68CC4E181AB7F8B36E45A287A41235841F5ECC